Featured Research

from universities, journals, and other organizations

Hay Fever May Be Best Treated With Self-adjusted Dosing

Date:
October 5, 2008
Source:
American Academy of Otolaryngology -- Head and Neck Surgery
Summary:
Hay fever, the often seasonal allergy that affects between 10 and 20 percent of the American population, is best controlled through a course of patient-adjusted dosing, according to new research published in the September 2008 edition of Otolaryngology -- Head and Neck Surgery.

Hay fever, the often seasonal allergy that affects between 10 and 20 percent of the American population, is best controlled through a course of patient-adjusted dosing, according to new research published in the September 2008 edition of Otolaryngology – Head and Neck Surgery.

During the study by Thai researchers, hay fever, known clinically as allergic rhinitis, was observed in 69 patients, who were then treated over the course of 28 days with the intranasal corticosteroid triamcinolone acetonide. Patients with mild symptoms were instructed to use the treatment only after symptoms occurred once a day; patients with more severe symptoms were told to continue morning daily dosage until they were symptom-free for 24 hours. However, as opposed to the normally prescribed once-daily dose, patients were instructed to adjust their use pattern based on the frequency and severity of symptoms and it was emphasized to them not to tolerate any mild or transient symptoms. As a result, during the course of the study, all patients saw improvement in their nasal symptom scores (which include blocked sinuses, rhinorrhea/runny nose, sneezing, and nasal itching).

The authors believe this in this self-adjusted dose regimen, which allows patients to increase or decrease the regularity of their dose based on their level of symptoms, the intranasal corticosteroids remain effective, while the treatment prevents priming responses and increased sensitivity that might otherwise occur over time. As a result, the authors determined that almost maximal symptomatic control could be achieved with three-fourths of the recommended regular once-daily dose by varying the daily dosage according to the severity of disease. They believe this approach would be a reasonable way to optimize both treatment efficacy and patient compliance.

Allergic rhinitis occurs when the body's immune system over-responds to specific, non-infectious particles such as plant pollens, molds, dust mites, and animal hair, among others. This causes skin redness and swollen membranes in the nasal passages, combined with sneezing and congestion. It is estimated that hay fever accounts for approximately 2 percent of all visits to a doctor's office.


Story Source:

The above story is based on materials provided by American Academy of Otolaryngology -- Head and Neck Surgery. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Otolaryngology -- Head and Neck Surgery. "Hay Fever May Be Best Treated With Self-adjusted Dosing." ScienceDaily. ScienceDaily, 5 October 2008. <www.sciencedaily.com/releases/2008/10/081001093452.htm>.
American Academy of Otolaryngology -- Head and Neck Surgery. (2008, October 5). Hay Fever May Be Best Treated With Self-adjusted Dosing. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/10/081001093452.htm
American Academy of Otolaryngology -- Head and Neck Surgery. "Hay Fever May Be Best Treated With Self-adjusted Dosing." ScienceDaily. www.sciencedaily.com/releases/2008/10/081001093452.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins